These Houston employers reign supreme when it comes to the best workplaces. Photo by Scott Halleran/Getty Images

Houstonians looking for their next employment opportunity might want to consider these 22 Houston-based companies that were just named the best workplaces in Texas by Fortune Magazine and Great Place to Work.

David Weekley Homes was named the No. 1 large employer in Texas, with workers celebrating that their company goes "above and beyond in almost every way possible" and values trust more than anything else.

"They trust you to get your work done and you never feel guilty about having to leave early for a medical appointment, or to pick your kid up from school," the report says. "They trust you to get your work done while maintaining a normal personal life."

The report also speaks highly of the construction company's 401K matching plan, and that workers can become owners in the company after two years of employment.

The remaining Houston companies that make up the top three best large Texas employers include information technology providers Hewlett Packard Enterprise Company (No. 2), and real estate investors Camden Property Trust (No. 3).

Also earning a spot in the top 10 is Hilcorp Energy Company (No. 8).

Speaking on Camden Property Trust, employees in the report say their leaders have developed a "one-of-a-kind" workplace culture, similar to a large family.

"Our celebrations, conferences, meetings feel like a family reunion," the report says. "Our leaders truly care about each and every single person and make decisions with everyone's best interest in mind."

The Best Workplaces in Texas award, which saw some of the same companies on the 2022 list, is the only one of its kind in the U.S. that "selects winners based on how fairly employees are treated," according to a press release. The companies are evaluated based on how well they treat their employees across several factors, including race, gender, age, disability status, and more.

The other Houston-based companies that made it onto Fortune's Best Large Workplaces in Texas 2023 include Transwestern (No. 12), Cornerstone Home Lending, Inc. (No. 14), and KBR (No. 24).

Furthermore, 17 additional Houston employers made it onto Fortune's Best Small and Medium Workplaces in Texas ranking. While Dallas companies dominate the top three, Houston's continuing education and learning center Continued made it into No. 4.

"[Continued] provide[s] so many benefits to better our home and work-life balance," the report says. "There is also a great focus on appreciating diversity and inclusion."The other Houston employers that earned spots on Fortune's Best Small and Medium Workplaces in Texas 2023 report are:

  • No. 12 – Hilltop Residential
  • No. 13 – WizeHire
  • No. 14 – Republic State Mortgage Co.
  • No. 16 – E.A.G. Business Holdings, Incorporated
  • No. 23 – Venterra Realty
  • No. 26 – Optimum Consultancy Services
  • No. 39 – 9th Wonder
  • No. 40 – Entelligence
  • No. 52 – Detechtion Technologies
  • No. 53 – Tricon Energy
  • No. 57 – Eagle Point Solutions
  • No. 64 – Hatch Agency Real Estate
  • No. 66 – Simucase
  • No. 69 – Crestwood Equity Partners

Just outside Houston, Cypress-based Specialized Assessment and Consulting ranked No. 31 and TK Trailer Parts in Madisonville ranked No. 65 in the small and medium workplace report.The full list of 2023's best workplaces in Texas can be found on greatplacetowork.com.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston biotech company tests hard-to-fight cancer therapeutics

fighting cancer

A Houston-based, female-founded biotech company has developed a treatment that could prove to be an effective therapy for a rare blood cancer.

Cellenkos Therapeutics has completed promising Phase 1b testing of its Treg cell therapy, CK0804, in the fight against myelofibrosis. According to a news release from the Cellenkos team, the use of its cord-blood-derived therapeutics could signal a paradigm shift for the treatment of this hard-to-fight cancer.

Cellenkos was founded by MD Anderson Cancer Center physician and professor Simrit Parmar. Her research at the hospital displayed the ability of a unique subset of T cells’ capability to home in on a patient’s bone marrow, restoring immune balance, and potentially halting disease progression.

Myelofibrosis has long been treated primarily with JAK (Janus Kinase) inhibitors, medications that help to block inflammatory enzymes. They work by suppressing the immune response to the blood cancer, but don’t slow the progression of the malady. And they’re not effective for every patient.

“There is a significant need for new therapeutic options for patients living with myelofibrosis who have suboptimal responses to approved JAK inhibitors,” Parmar says. “We are greatly encouraged by the safety profile and early signs of efficacy observed in this patient cohort and look forward to continuing our evaluation of the clinical potential of CK0804 in our planned expansion cohort.”

The expansion cohort is currently enrolling patients with myelofibrosis. What exactly are sufferers dealing with? Myelofibrosis is a chronic disease that causes bone marrow to form scar tissue. This makes it difficult for the body to produce normal blood cells, leaving patients with fatigue, spleen enlargement and night sweats.

Myelofibrosis is rare, with just 16,000 to 18,500 people affected in the United States. But for patients who don’t respond well to JAKs, the prognosis could mean a shorter span than the six-year median survival rate outlined for the disease by Cleveland Clinic.

Helping myelofibrosis patients to thrive isn’t the only goal for Cellenkos right now.

The company seeks to aid people with rare conditions, particularly inflammatory and autoimmune disorders, with the use of CK0804, but also other candidates including one known as CK0801. The latter drug has shown promising efficacy in aplastic anemia, including transfusion independence in treated patients.

The company closed its $15 million series A round led by BVCF Management, based in Shanghai, in 2021. Read more here.

Pioneering Houston biotech startup expands to Brazil for next phase

On the Move

Houston biotech company Cemvita has expanded into Brazil. The company officially established a new subsidiary in the country under the same name.

According to an announcement made earlier this month, the expansion aims to capitalize on Brazil’s progressive regulatory framework, including Brazil’s Fuel of the Future Law, which was enacted in 2024. The company said the expansion also aims to coincide with the 2025 COP30, the UN’s climate change conference, which will be hosted in Brazil in November.

Cemvita utilizes synthetic biology to transform carbon emissions into valuable bio-based chemicals.

“For decades Brazil has pioneered the bioeconomy, and now the time has come to create the future of the circular bioeconomy,” Moji Karimi, CEO of Cemvita, said in a news release. “Our vision is to combine the innovation Cemvita is known for with Brazil’s expertise and resources to create an ecosystem where waste becomes opportunity and sustainability drives growth. By joining forces with Brazilian partners, Cemvita aims to build on Brazil’s storied history in the bioeconomy while laying the groundwork for a circular and sustainable future.”

The Fuel of the Future Law mandates an increase in the biodiesel content of diesel fuel, starting from 15 percent in March and increasing to 20 percent by 2030. It also requires the adoption of Sustainable Aviation Fuel (SAF) and for domestic flights to reduce greenhouse gas emissions by 1 percent starting in 2027, growing to 10 percent reduction by 2037.

Cemvita agreed to a 20-year contract that specified it would supply up to 50 million gallons of SAF annually to United Airlines in 2023.

"This is all made possible by our innovative technology, which transforms carbon waste into value,” Marcio Da Silva, VP of Innovation, said in a news release. “Unlike traditional methods, it requires neither a large land footprint nor clean freshwater, ensuring minimal environmental impact. At the same time, it produces high-value green chemicals—such as sustainable oils and biofuels—without competing with the critical resources needed for food production."

In 2024, Cemvita became capable of generating 500 barrels per day of sustainable oil from carbon waste at its first commercial plant. As a result, Cemvita quadrupled output at its Houston plant. The company had originally planned to reach this milestone in 2029.

---

This story originally appeared on our sister site, EnergyCapitalHTX.